Lipid lowering with inclisiran: a real-world single-centre experience

OBJECTIVE: The reduction in circulating low-density lipoprotein cholesterol (LDL-c) is the primary aim of lipid-lowering therapies as a method of atherosclerotic cardiovascular disease risk reduction. Inclisiran is a new and potent lipid-lowering drug that is shown to be effective in reducing LDL-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Padam, Pritpal, Barton, Lucy, Wilson, Stewart, David, Alessia, Walji, Shahenaz, de Lorenzo, Ferruccio, Ray, Kausik K, Jones, Ben, Cegla, Jaimini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Coronary Artery Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748986/
https://www.ncbi.nlm.nih.gov/pubmed/36600646
http://dx.doi.org/10.1136/openhrt-2022-002184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748986/
https://www.ncbi.nlm.nih.gov/pubmed/36600646
http://dx.doi.org/10.1136/openhrt-2022-002184

Ejemplares similares